Alastair Carruthers1, Jean Carruthers. 1. Department of Dermatology and Skin Science, University of British Columbia, 943 W Broadway, Suite 820, Vancouver, British Columbia V5Z 4E1, Canada. alastair@carruthers.net
Abstract
BACKGROUND: Treating multiple upper facial rhytids at one time is common, but has not been researched extensively. OBJECTIVE: We sought to compare the safety, efficacy, and effect duration of 3 botulinum neurotoxin type A (BoNTA) doses in treating multiple upper facial rhytids. METHOD:Sixty women, randomized to 32, 64, or 96 U total doses, were assessed at baseline, week 2, week 4, then every 4 weeks. The primary efficacy measure was proportion of responders on the patient global assessment of improvement. Adverse events (AEs) were monitored. RESULTS: All BoNTA doses were effective and safe. Significant between-group differences occurred in the percentage of responders (96 U: 71%, 64 U: 61%, 32 U: 26%; P = .0007). Adverse events did not differ significantly among groups; no serious treatment-related adverse events occurred. LIMITATIONS: BoNTA doses were fixed and not tailored to individuals. CONCLUSION: These results confirm the efficacy and safety of 3 doses of BoNTA for treating upper facial rhytids in female patients; higher doses afforded greater benefit.
RCT Entities:
BACKGROUND: Treating multiple upper facial rhytids at one time is common, but has not been researched extensively. OBJECTIVE: We sought to compare the safety, efficacy, and effect duration of 3 botulinum neurotoxin type A (BoNTA) doses in treating multiple upper facial rhytids. METHOD: Sixty women, randomized to 32, 64, or 96 U total doses, were assessed at baseline, week 2, week 4, then every 4 weeks. The primary efficacy measure was proportion of responders on the patient global assessment of improvement. Adverse events (AEs) were monitored. RESULTS: All BoNTA doses were effective and safe. Significant between-group differences occurred in the percentage of responders (96 U: 71%, 64 U: 61%, 32 U: 26%; P = .0007). Adverse events did not differ significantly among groups; no serious treatment-related adverse events occurred. LIMITATIONS: BoNTA doses were fixed and not tailored to individuals. CONCLUSION: These results confirm the efficacy and safety of 3 doses of BoNTA for treating upper facial rhytids in female patients; higher doses afforded greater benefit.
Authors: Cristina Pires Camargo; Jun Xia; Caroline S Costa; Rolf Gemperli; Maria Dc Tatini; Max K Bulsara; Rachel Riera Journal: Cochrane Database Syst Rev Date: 2021-07-05
Authors: Koenraad De Boulle; Alastair Carruthers; Nowell Solish; Jean Carruthers; Wolfgang G Phillipp-Dormston; Steven Fagien; Sara Sangha; Michael Silberberg; Cheri Mao Journal: Plast Reconstr Surg Glob Open Date: 2020-03-20